Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹884 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
GMM Pfaudler reported a stable Q3 FY26 with revenue and profitability in line with expectations, but the highlight was a strong order intake of ₹961 crore (+9% QoQ, +20% YoY), driving the backlog to a record ₹2,205 crore (+27% YoY). The 9-month revenue grew 8% YoY and EBITDA rose 14% YoY, with margins improving to 12.7% (9M basis) from 12% last year. Diversification into non-traditional sectors (defense, nuclear, metals) now accounts for 50% of orders, offsetting weakness in chemicals and Europe. Management expects Q4 to be strong in India and maintains a medium-term EBITDA margin target of 16-18%, though near-term headwinds from global uncertainty and underperforming units (Germany, China) persist. Key risk: a prolonged downturn in European chemical/pharma markets could delay margin recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated the target from the capital markets day, driven by higher-margin mixing and systems businesses and turnaround of underperforming units.
- Management expects Q4 to be a strong quarter in India in terms of revenue and shipment, supported by the current backlog.
- Management expects the strong order intake trend to continue in Q4, positioning the company with a 30% higher backlog for FY27.
- The restructuring in Germany will reduce ~30% of the wage bill, with full-year savings of ₹25 crore expected in FY27.
Risks flagged
- Europe remains slow and uncertain, especially in traditional chemical and pharma segments, which could delay margin recovery.
- Germany and China continue to drag on group EBITDA margins; restructuring benefits may take time to materialize.
- Analysts noted a sequential decline in gross margins (60.1% vs 63% in prior quarters), which management attributed to mix but could persist.
- Management acknowledged that the global environment remains challenging and could affect the pace of order conversion to revenue.
Key quotes
- Today our backlog stands at 2,205 crores, the highest it's ever been which is 27% higher than previous year.
- We are confident that we also bring it slowly up again in the next financial year already. But the full achievement the target by when we will reach it it also depends on the global economic situation.
- A company that was famous and only known for glass line today has 50% of its business coming from non-glass line non-pharma non-chemical.
Research modules